WO2024089609 - GLYCOENGINEERED FC VARIANT POLYPEPTIDES WITH ENHANCED EFFECTOR FUNCTION
National phase entry:
Publication Number
WO/2024/089609
Publication Date
02.05.2024
International Application No.
PCT/IB2023/060739
International Filing Date
25.10.2023
Title **
[English]
GLYCOENGINEERED FC VARIANT POLYPEPTIDES WITH ENHANCED EFFECTOR FUNCTION
[French]
POLYPEPTIDES VARIANTS FC GLYCOMODIFIÉS À FONCTION EFFECTRICE AMÉLIORÉE
Applicants **
ABLYNX N.V.
Inventors
JAWORSKI, Julie A.
KATHURIA, Sagar V.
PARK, Sunghae
ZHOU, Qun
Priority Data
63/419,188
25.10.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 6513 | |
| EPO | Filing, Examination, Granting | 152038 | |
| Japan | Filing, Examination, Granting | 5127 | |
| South Korea | Filing, Examination, Granting | 9665 | |
| USA | Filing, Examination, Granting | 32840 |
Total:
206,183
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure provides glycoengineered Fc domain variants comprising one or more oligomannose-type N-glycans and an Fc domain mutation. The present disclosure also provides nucleic acids encoding Fc domain variants and host cells for making Fc domain variants. Methods for increasing the yield of Fc domain variants, and methods of using Fc domain variants to treat disease, are also provided.[French]
La présente divulgation concerne des variants de domaine Fc glycomodifiés comprenant un ou plusieurs N-glycanes de type oligomannose et une mutation de domaine Fc. La présente divulgation concerne également des acides nucléiques codant pour des variants de domaine Fc et des cellules hôtes pour la fabrication de variants de domaine Fc. La divulgation concerne également des procédés pour augmenter le rendement de variants de domaine Fc et des procédés d'utilisation de variants de domaine Fc pour traiter une maladie.